[A21-35] Pembrolizumab (Hodgkin lymphoma) - Benefit assessment according to §35a Social Code Book V
Last updated 01.07.2021
Project no.:
A21-35
Commission:
Commission awarded on 31.03.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adult and paediatric patients aged 3 years and older with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplant or following at least two prior therapies when autologous stem cell transplant is not a treatment option
- Adults for whom brentuximab vedotin is the suitable therapy according to physician’s choice: hint of non-quantifiable added benefit.
- Adults for whom brentuximab vedotin is not the suitable therapy according to physician’s choice: added benefit not proven.
- Children and adolescents aged 3 years and older: added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Federal Joint Committee (G-BA)
2021-09-16 A G-BA decision was published.